Quicker Remission With Tofacitinib vs Vedolizumab in Ulcerative Colitis: Study Quicker Remission With Tofacitinib vs Vedolizumab in Ulcerative Colitis: Study

Tofacitinib achieves higher clinical and biochemical remission rates than vedolizumab for patients with anti-TNF-exposed ulcerative colitis, although the effect diminishes over time, say Dutch scientists.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news